^
    2ms
    CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Baylor College of Medicine | Trial completion date: Jul 2026 --> Jul 2027
    Trial completion date
    2ms
    Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Jennifer Woyach | Initiation date: May 2026 --> Sep 2026
    Trial initiation date
    |
    clonoSEQ®
    |
    Venclexta (venetoclax) • nemtabrutinib (MK-1026)
    2ms
    A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant (clinicaltrials.gov)
    P1, N=46, Recruiting, City of Hope Medical Center | Trial completion date: Feb 2030 --> May 2028 | Trial primary completion date: Feb 2030 --> May 2028
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Triplex (CMV-MVA vaccine)
    2ms
    CD20-Negative Primary Intestinal Diffuse Large B-cell Lymphoma With TP53 Mutation in Poorly Controlled Celiac Disease: A Diagnostic Challenge. (PubMed, Cureus)
    The final diagnosis was CD20-negative primary intestinal large B-cell lymphoma with a TP53 mutation arising in the context of poorly controlled CD, a combination that, to the best of our knowledge, has not been previously reported in the literature. This case highlights the diagnostic challenges posed by intestinal lymphomas associated with CD and emphasizes the importance of integrating histopathological, immunophenotypic, and molecular findings to achieve an accurate diagnosis and provide prognostic assessment.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • PAX5 (Paired Box 5) • SDC1 (Syndecan 1) • CD79A (CD79a Molecule) • IRF4 (Interferon regulatory factor 4) • ITGAE (Integrin Subunit Alpha E) • CD2 (CD2 Molecule)
    |
    TP53 mutation • CD20 negative
    2ms
    A deep learning-based prognostic model for diffuse large B-cell lymphoma incorporating PET/CT imaging features. (PubMed, Front Oncol)
    DCA revealed that this fusion model offers a significant clinical net benefit for prognostic risk prediction in DLBCL patients over a wide threshold probability range of 0.05-0.900. The fusion model, combining PET/CT deep features with clinical characteristics, is a dependable prognostic tool for DLBCL, holding substantial promise for clinical application and personalized treatment.
    Journal
    |
    B2M (Beta-2-microglobulin)
    2ms
    Waldenström macroglobulinemia-associated renal AL amyloidosis: a case report and literature review. (PubMed, Front Immunol)
    Following multidisciplinary consultation, the patient was treated with the bendamustine plus rituximab (BR) regimen. Second, for WM patients with renal AL amyloidosis, choosing BR regimen as the first-line treatment is reasonable. However, during the treatment process, it is essential to closely monitor and actively prevent the adverse effects of this regimen, particularly severe infections which may have fatal consequences.
    Review • Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    |
    Rituxan (rituximab) • bendamustine
    2ms
    Predicting CAR-T outcomes in R/R DLBCL: a multicenter real-world study of a 5-index model. (PubMed, Front Immunol)
    The 5‑index risk model demonstrated robust predictive ability in a real‑world setting, providing a reliable basis for personalized treatment decisions in Chinese DLBCL patients undergoing CAR‑T. Future work will focus on further optimizing the model and conducting multi‑regional validation.
    Retrospective data • Journal • Real-world evidence
    |
    TP53 (Tumor protein P53)
    2ms
    Transcriptomic profiling of an in vivo diffuse large B-cell lymphoma model reveals molecular programs underlying CNS dissemination. (PubMed, Ann Hematol)
    Patient-derived transcriptomes exhibited enrichment of pathways that were functionally related to the gene signatures observed in the xenograft model. These findings suggest that CNS-preferential dissemination in DLBCL is associated with coordinated signaling involving PI3K/ARF6 activation and suppression of S1P-mediated pathways, providing molecular insights with potential implications for risk stratification and therapeutic targeting in sCNSi.
    Preclinical • Journal
    |
    mTOR (Mechanistic target of rapamycin kinase) • LY9 (Lymphocyte Antigen 9)
    2ms
    Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas (clinicaltrials.gov)
    P1, N=14, Recruiting, Abramson Cancer Center at Penn Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    HALTAging-1: Halt Aging in Survivors of Blood Cancers (clinicaltrials.gov)
    P=N/A, N=180, Recruiting, University of Nebraska | Phase classification: P2 --> P=N/A
    Phase classification
    2ms
    Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=66, Not yet recruiting, Ou Bai, MD/PHD
    New P2 trial
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Inokai (orelabrutinib) • Polivy (polatuzumab vedotin-piiq) • thiotepa • Anruixi (zuberitamab)
    2ms
    Utility of MEF2B immunohistochemistry in distinguishing follicular lymphoma and marginal zone lymphoma in diagnostically challenging cases. (PubMed, J Hematop)
    MEF2B immunohistochemistry can aid in distinguishing FL from MZL in diagnostically challenging cases.
    Journal
    |
    BCL6 (B-cell CLL/lymphoma 6)